Close Menu

rosacea

The suit is the second filed by the plaintiffs this year against a generic drug manufacturer for allegedly infringing patents protecting Galderma's rosacea treatment Oracea by filing an ANDA for a generic version of the drug.

Although SUNY and NYU's financial stake in the proceedings is unclear, they are seeking to protect a royalty stream that dates back to a 1992 licensing agreement with Galderma predecessor Collagenix Pharmaceuticals for some of the patents protecting Oracea, which exceeded $50 million in sales in 2007.

Nature News reports on how meeting cancellations and related costs are affecting scientific societies.

In a new ruling, Canada's Supreme Court upheld the country's genetic non-discrimination law, the Canadian Press reports.

COVID-19 vaccine developers aim to avoid a complication that has affected efforts to develop vaccines for other diseases, the Wall Street Journal reports.

In PLOS this week: analysis of insertions throughout Shigella genomes, antigen production in malaria parasites, and more.